Janssen Korea, Ltd., Korea
Quick facts
Marketed products
- decitabine injection · Oncology
Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells. - Fentanyl D-trans
- Fentanyl matrix
- Hydromorphone HCl OROS · Pain Management
Hydromorphone HCl OROS is an opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and is formulated as an extended-release osmotic system for sustained pain relief. - Oxybutynin chloride OROS
- Paliperdidone ER · Psychiatry
Paliperidone ER is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms. - Propranolol booster
- Risperidone long acting injectables · Psychiatry/Neurology
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. - Topiramate Slow
- Topiramate Standard · Neurology
Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability. - Tramadol HCl/acetaminophen Extended Release · Pain Management
Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects. - Tramadol hydrochloride/ Acetaminophen · Pain Management
Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects. - Tramadol Hydrochloride Plus Acetaminophen
Phase 3 pipeline
- Tramadol HCl/Acetaminophen IR · Pain management
Tramadol HCl/Acetaminophen IR is a combination of a centrally acting opioid analgesic and a non-opioid analgesic that works by affecting the central nervous system to relieve pain.
Phase 2 pipeline
- Hydromorphone HCI OROS · Pain management
μ-opioid receptor agonist - Normal control
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: